What you need to know about side effects, rib infections and more

Mine called Paxlovid’s 88% efficacy against COVID-related hospitalizations and deaths a “surprising figure.”

In a study of 2,085 unvaccinated adults, only 8 or 0.8% had a pre-existing medical condition (or were just older), compared with 66 or 6% of those who received a placebo were hospitalized with COVID or died of some cause.

The good news is that Paxlovid seems to be holding on to real-world settings.

A May 17 unpublished study of about 94,000 elderly or immunocompromised COVID patients in Hong Kong showed that people treated with Paxlovid had a 21% lower risk of hospitalization.

Another non-reviewed study published on June 1 found that Paxlovid was associated with a 67% and 81% reduction in COVID hospitalizations and deaths in people aged 65 and older. (But the benefits have not been seen in young people.)

Although the drug has only been studied in unvaccinated people, there is no reason to believe that it will not work well in vaccinated people, Mina said.

“People who are vaccinated are like those who are infected with a viral infection,” Mina said. “Access to drugs that reduce viral replication en masse, hospitalization and mortality by all accounts is available to all people infected, regardless of their vaccination status.”

Rebound infections may occur after Paxlovid

You may have heard that some people taking Paxlovid may have “recurrent infections,” which means that people who complete five days of treatment with Paxlovid will have a positive test two to eight days after the negative test.

Symptoms don’t always reappear, but according to the CDC’s May 24 health council, they certainly are possible.

Infections that occur after taking Paxlovid are mild and improve or resolve within three days; none was harsh. The CDC said there was no evidence that Paxlovid or other therapies would require further treatment.

However, recurrent infections may contribute to the further spread of the coronavirus, but it is unknown how much. In addition, they are generally uncomfortable and send people to wear the mask for an additional five days and 10 days, which is recommended for re-isolation.

We can still learn a lot about why recurrent infections occur, but Mina Paxlovid’s treatment suggests that it is not enough to completely eradicate the virus from human systems.

“The drug can act as a crutch during your current infection, so when you stop taking the drug, your immune system reacts as suddenly as a new infection,” Mina said. “If we leave the medicine on for a few more days, it could give the body enough time to destroy all of the virus.”

Dr. Raj and Indra Noyi, public health professors at Albert Co., Yale School of Public Health, told BuzzFeed News that a reservoir of the virus could not touch Paxlovid anywhere in the body and could lead to a resurgence of symptoms and / or a positive test. Results after treatment. This theory may be more common in people who are naturally high in viral load.

According to me, health care providers may consider extending Paxlovid treatment to 8 or 10 days.

Despite treatment with Paxlovid, the CDC said that in some people, a “brief recurrence of symptoms of coronavirus infection may be part of a natural history.”

Omicron could also be to blame, Mina said. Omicron avoids infection and the immune system more than Delta, so your immune system may find it harder to get rid of KOVID when working with Paxlovid.

People also experience Omicron symptoms earlier than previous options, Mina said, which means they start Paxlovid treatment earlier than infection. Thus, there is a possibility that we are not giving our immune systems enough time to respond strongly to treatment.

The CDC also recommends that Mina and Co. still take Paxlovid to people at high risk of COVID who are not hospitalized.

How is paxlovid compared to other COVID treatments?

There are a number of ways to treat KOVID, but whether one is better than the other depends on the patient’s medical needs and history, the availability of treatment, and the options available in a particular area.

After all, Paxlovid has become the first choice therapy for many people.

The National Institutes of Health guidelines for the treatment of COVID state that Paxlovid is the preferred treatment for non-hospitalized patients. The next line consists of remdesivir (brand name Veklury), which is given intravenously and has been shown to be 87% effective against non-hospitalized deaths with a high risk of COVID hospitalization and severe disease. Remdesivir can also be used in hospitalized patients.

Another treatment is bebtelovimab, a new monoclonal antibody that can be given to non-hospitalized patients if Paxlovid or remdesivir is not available or is not safe for the patient. There are no data yet on the efficacy of Bebtelovimab, but the NIH said it is “active” against all Omicron subvariants in the laboratory.

Although Lagevrio takes other new antiviral pills, studies have shown that it is only 30% effective against hospitalization and death associated with COVID, so it should be used as a last resort.

How to take Paxlovid

On March 8, Biden’s administration launched the “Test for Treatment,” an initiative that allows people to be tested for COVID at a pharmacy-based clinic, public health center, or long-term medical facility and receive antiviral drugs such as Paxlovid immediately if tested. right.

Through the clinics participating in the initiative, people are only allowed to take Lagevrio and Paxlovid, they are free regardless of whether you have insurance or not.

Here you will find places close to you that are part of the Test to Treat initiative.

You can also go to a doctor (if available) who will prescribe Paxlovid, which you can get at your local pharmacy.

If you take a quick COVID test at home and it is positive, you can go to free telemedicine via eMed, said Mina, during which a medical professional can prescribe treatment. (You need to buy a quick test from eMed first, but the rest is free.)

Paxlovid shipments have not been able to meet demand in the U.S. for a long time, but Pfizer officials have increased production in recent weeks. According to Mina, information about the initial shortage prevented many doctors from prescribing the drug because of a lack of use. “It led to a misunderstanding of this really powerful drug for months,” he said.

The number of prescriptions for Paxlovid via email to BuzzFeed News, a spokesman for the Health and Welfare Service, increased from 64,000 per week in late April to 184,000 per week by the end of May.

About 300 test sites have been added since the beginning of May, bringing the total to about 2,600, which is expected to grow, the spokesman said.

Can Paxlovid Reduce the Chance of Prolonged COVID Development?

Although no information has been gathered as to whether Palovid can reduce your chances of developing long-term KOVID, we should expect both Mina and Co to do so.

“We need to prevent and really prevent early aggressive treatment to eliminate the viral load of the virus, it should completely reduce the symptoms of prolonged COVID until it takes over you a lot,” Mina said. “Just the fact that the viral load is kept to a very small amount should only lead to a better outcome in terms of reducing the likelihood of COVID lasting longer.”

Co admitted that we do not understand why some people develop a long-lasting COVID, but knowing the link between the condition and the viral load, Paxlovid can help in this regard.

Does Paxlovid work against different COVID options?

Clinical trials to determine the effectiveness of Paxlovid were conducted from July to early December, before the U.S. pandemic became more prevalent in the Omicron variant. This means that what we know about Paxlovid’s ability to fight the virus is based on infections with the Delta variant.

But the truth is, all options are drug-sensitive and sensitive, Mina said. This is because it targets another part of the coronavirus, at least if it is Omicron, and does not undergo mutations.

“It’s very easy to make noise and hear all the negative things, but at the end of the day, the test results were wrong,” Mina said. “People still saved their lives in Pakslovid.”

But that doesn’t mean future options won’t make the drug resistant, and neither Mina nor Co., the CDC, said there was any evidence that this was happening.

Leave a Comment

Your email address will not be published.